{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"7","upperLimit":"797","value":"74"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"16"}],"units":"Participants"}],"description":"Interval from Date of start of treatment to date of disease progression or death from any cause. Disease progression is defined as at least 20% increase in sum of longest diameter of target lesions or appearance of any new lesions. Subjective determination of significant worsening of disease-related symptoms was considered clinical disease progression.","dispersionType":"Full Range","groups":[{"description":"Subjects who received Temsirolimus MTD, 20 mg/m\\^2 in Phase I of the study and all subjects in the Phase II study were included from both Phase I and Phase II of the study who were not taken off study for early toxicity were included. Two of the eighteen subjects who were treated at the MTD were excluded.","id":"OG000","title":"Subjects Who Were Treated at the Temsirolimus MTD, 20 mg/m^2"}],"paramType":"MEDIAN","populationDescription":"The number of analyzed participants does not include the 2 participants treated at the MTD who stopped treatment for early disease-related adverse events.","reportingStatus":"POSTED","timeFrame":"up to 3 years","title":"Median Progression-free Survival of Subjects Who Were Treated at the Temsirolimus MTD, 20 mg/m^2","type":"SECONDARY","unitOfMeasure":"days"}